Ovarian Cancer section

Ovarian Cancer News & Features

Researchers identify biological indicator of response to new ovarian cancer drug

A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.

Ovarian cancer patients may benefit from pelvic radiotherapy

Ovarian clear cell adenocarcinoma (CCA), a rare and aggressive form of ovarian cancer, may be treated by employing pelvic radiotherapy (RT).

Cancer-killing virus and doxorubicin act synergistically on metastatic ovarian cancer

Cancer-killing virus and doxorubicin act synergistically on metastatic ovarian cancer

A new approach to treatment using a cancer-killing virus combined with a chemotherapy drug may offer hope to those with advanced and recurrent forms of metastatic ovarian cancer.

BRCA-related tumors respond to olaparib

Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.

FDA approves Avastin for platinum-resistant, recurrent ovarian cancer

FDA approves Avastin for platinum-resistant, recurrent ovarian cancer

FDA has approved Avastin (bevacizumab) for treatment of platinum-resistant recurrent epithelial ovarian cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs